NAMSW — NewAmsterdam Pharma Co N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1936258 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 19,164,000 | — | -44,188,000 | -17,389,000 | 687,985,000 | 423,129,000 | 57,203,000 |
| Jun 2026 | 3,701,000 | — | -64,864,000 | -64,135,000 | 704,452,000 | 424,151,000 | 73,030,000 |
| Mar 2026 | 3,040,000 | — | -58,420,000 | -48,441,000 | 732,643,000 | 457,607,000 | 67,421,000 |
| Dec 2025 | 32,000 | — | -65,980,000 | -74,923,000 | 769,284,000 | 490,002,000 | 85,853,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-150,466,000
Investing CF
$-3,713,000
Financing CF
$41,241,000
CapEx
$-395,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-892,355,000
Inventory
—
Receivables
$26,995,000
ST Investments
$205,113,000
EBIT TTM
$-233,452,000
Pretax Income TTM
$-203,681,000
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$7,121,000
EBITDA
$-244,163,008
Free Cash Flow
$-45,358,376
Enterprise Value
—
Total Cash
$633,854,016
Total Debt
$82,000
Shares Out
—
Trailing EPS
—
Book Value
$5.97
ROE
-36.8%
ROA
-20.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 22,503,000 | -225,683,000 | -203,819,000 | 769,284,000 | 85,853,000 | 683,431,000 | -147,783,000 |
| Dec 2024 | 45,563,000 | -176,289,000 | -241,598,000 | 864,620,000 | 107,120,000 | 757,500,000 | -158,564,000 |
| Dec 2023 | 14,090,000 | -182,967,000 | -176,937,000 | 347,097,000 | 58,704,000 | 288,393,000 | -141,218,000 |
| Dec 2022 | 102,694,000 | -3,557,000 | -22,634,000 | 478,497,000 | 48,431,000 | 430,066,000 | 10,665,000 |
TTM Snapshot
Revenues TTM
$7,121,000
NetIncome TTM
$-259,504,000
OpCashFlow TTM
—
Assets (Latest)
$704,452,000
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.26T | $1415.55 | — |
| JNJ | JOHNSON & JOHNSON | $670.92B | $278.70 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
News headlines (Yahoo Finance, 1h cache)
The Billionaire-Backed Pharma Play Sitting on a $640M Cash Pile at 52-Week Lows
2026-11-07 23:26 · Yahoo
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:01 · Yahoo
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 12:55 · Yahoo
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
2026-11-04 12:30 · Yahoo
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
2026-11-03 13:00 · Yahoo
Does NewAmsterdam Pharma’s (NAMS) Genotype-Targeted SPINOZA Trial Reframe Obicetrapib’s Long-Term Alzheimer’s Strategy?
2026-10-13 23:22 · Yahoo
Group 1 Automotive and 4 More Stocks See Action From Activist Investors
2026-10-02 22:02 · Yahoo
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
2026-09-29 12:00 · Yahoo
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?
2026-09-23 01:20 · Yahoo
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
2026-09-21 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.